SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Liedberg F.)
 

Sökning: WFRF:(Liedberg F.) > European Associatio...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005984naa a2200625 4500
001oai:lup.lub.lu.se:7aed0f74-456d-4795-824e-18135b5f9ca4
003SwePub
008230523s2023 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/7aed0f74-456d-4795-824e-18135b5f9ca42 URI
0247 a https://doi.org/10.1016/j.eururo.2023.03.0132 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Rouprêt, Morganu Pitié-Salpêtrière University Hospital4 aut
2451 0a European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma : 2023 Update
264 1b Elsevier BV,c 2023
520 a Context: The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in evidence-based management of UTUC. Objective: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. Evidence acquisition: The recommendations provided in these guidelines are based on a review of the literature via a systematic search of the PubMed, Ovid, EMBASE, and Cochrane databases. Data were searched using the following keywords: urinary tract cancer, urothelial carcinomas, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, (neo)adjuvant treatment, instillation, recurrence, risk factors, metastatic, immunotherapy, and survival. The results were assessed by a panel of experts. Evidence synthesis: Even though data are accruing, for many areas there is still insufficient high-level evidence to provide strong recommendations. Patient stratification on the basis of histology and clinical examination (including imaging) and assessment of patients at risk of Lynch syndrome will aid management. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk UTUC and two functional kidneys. In particular, for patients with high-risk or metastatic UTUC, new treatment options have become available. In high-risk UTUC, platinum-based chemotherapy after radical nephroureterectomy, and adjuvant nivolumab for unfit or patients who decline chemotherapy, are options. For metastatic disease, gemcitabine/carboplatin chemotherapy is recommended as first-line treatment for cisplatin-ineligible patients. Patients with PD-1/PD-L1–positive tumours should be offered a checkpoint inhibitor (pembrolizumab or atezolizumab). Conclusions: These guidelines contain information on the management of individual patients according to the current best evidence. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen according to the risk stratification of these tumours. Patient summary: Cancer of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, timely and appropriate diagnosis is most important. A number of known risk factors exist.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653 a (Neo)adjuvant therapy
653 a Chemotherapy
653 a Genetic screening
653 a Immunotherapy
653 a Management
653 a Prognostic factors
653 a Renal pelvis
653 a Surgery
653 a Ureter
653 a Urothelial carcinoma
7001 a Seisen, Thomasu Pitié-Salpêtrière University Hospital4 aut
7001 a Birtle, Alison J.u University of Manchester4 aut
7001 a Capoun, Otakaru Vienna General Hospital / University Hospital Vienna,General University Hospital in Prague4 aut
7001 a Compérat, Eva M.u Vienna General Hospital / University Hospital Vienna,Hopital Tenon,General University Hospital in Prague4 aut
7001 a Dominguez-Escrig, José L.u Instituto Valenciano de Oncologia4 aut
7001 a Gürses Andersson, Irene4 aut
7001 a Liedberg, Fredriku Lund University,Lunds universitet,Urologi - blåscancer, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Urinblåsecancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Urology - urothelial cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Urothelial cancer,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)urok-fli
7001 a Mariappan, Paramananthanu Western General Hospital4 aut
7001 a Hugh Mostafid, A.4 aut
7001 a Pradere, Benjaminu Medical University of Vienna4 aut
7001 a van Rhijn, Bas W.G.u Antoni Van Leeuwenhoek Hospital,University of Regensburg4 aut
7001 a Shariat, Shahrokh F.u University Hospital Motol,Vienna General Hospital / University Hospital Vienna4 aut
7001 a Rai, Bhavan P.u Freeman Hospital4 aut
7001 a Soria, Francescou University of Turin4 aut
7001 a Soukup, Viktoru General University Hospital in Prague,Vienna General Hospital / University Hospital Vienna4 aut
7001 a Wood, Robbert G.4 aut
7001 a Xylinas, Evanguelos N.u Université Paris Cité4 aut
7001 a Masson-Lecomte, Alexandrau Université Paris Cité4 aut
7001 a Gontero, Paolou University of Turin4 aut
7102 a Pitié-Salpêtrière University Hospitalb University of Manchester4 org
7730 t European Urologyd : Elsevier BVg 84:1, s. 49-64q 84:1<49-64x 0302-2838
8564 u http://dx.doi.org/10.1016/j.eururo.2023.03.013y FULLTEXT
8564 8u https://lup.lub.lu.se/record/7aed0f74-456d-4795-824e-18135b5f9ca4
8564 8u https://doi.org/10.1016/j.eururo.2023.03.013

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy